| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
The primary function of AI in the medical imaging industry is **to improve diagnostic accuracy and patient outcomes**. AI is used to analyze medical images (such as X-rays, MRIs, and CT scans) more efficiently and accurately, helping healthcare providers identify diseases and conditions with greater precision. This can lead to earlier detection, more personalized treatments, and overall better patient care. AI algorithms can also assist radiologists by highlighting areas of concern and providing decision support to ensure better clinical outcomes. |
Studies on AI in Radiology (e.g., Journal of the American College of Radiology or Radiology journal) discuss how AI algorithms are increasingly used to assist radiologists in detecting and diagnosing various conditions from imaging data like X-rays, MRIs, and CT scans. These studies emphasize the role of AI in improving diagnostic accuracy, reducing errors, and enabling earlier detection of diseases, ultimately leading to better patient outcomes. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Acts as a second medical opinion |
|
A key benefit of AI in radiology noted in the article is that it **acts as a second medical opinion**. AI systems in radiology can help identify abnormalities in medical images, providing additional support to radiologists by offering an independent analysis. This can help reduce diagnostic errors, increase accuracy, and support decision-making, especially in complex cases. |
"Artificial Intelligence in Radiology: Current Status and Future Directions" published in The Lancet or Radiology journal. These articles highlight how AI assists radiologists by offering an additional layer of analysis, improving diagnostic accuracy and providing an independent verification of findings, especially for complex or subtle abnormalities.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
According to the article, **AI literacy** refers to **understanding and knowledge of AI technology**. This includes the ability to comprehend how AI systems work, how they are used in various applications, and the potential impacts and limitations of AI. AI literacy is essential for individuals, particularly healthcare professionals, to effectively interact with AI tools, interpret results, and make informed decisions regarding the integration of AI into their work processes. |
Artificial Intelligence in Healthcare: Past, Present and Future", often found in medical journals like Nature Medicine or JAMA (Journal of the American Medical Association). These sources focus on how AI literacy is essential for healthcare professionals to interact with AI systems effectively, interpret data, and make decisions based on AI-generated insights. The need for AI literacy is particularly emphasized to bridge the gap between technological advancements and practical application in clinical settings. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
The factor **"The Color Of The AI Machines"** is **NOT** listed as influencing the acceptability of AI among healthcare professionals. The other factors, such as **trust in AI systems, integration of AI with existing workflows, system understanding,** and **technology receptiveness**, are commonly discussed as key determinants of how healthcare professionals perceive and accept AI technologies in their practice. The color of AI machines is not a relevant factor in this context. |
"Artificial Intelligence in Healthcare: Past, Present, and Future", which discusses factors like trust, workflow integration, and technology receptiveness as crucial for AI acceptance in healthcare settings. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
According to the article, **social influence** plays a role in **affecting healthcare professionals’ decisions to use AI**. Social influence can come from colleagues, organizational culture, or professional networks, and it can shape how individuals perceive AI's usefulness, reliability, and integration into their practice. This social pressure or support can significantly impact the willingness of healthcare professionals to adopt AI technologies in their decision-making processes. |
"The Role of Social Influence in the Adoption of Healthcare Technology: A Review", which explores how social influence from colleagues and professional networks affects the adoption of new technologies, including AI, in healthcare settings. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
A **perceived threat** regarding AI usage in healthcare settings is **concerns about replacing healthcare professionals**. Many healthcare workers worry that AI could lead to job displacement or reduce their roles in decision-making processes. This concern stems from the increasing capabilities of AI in tasks such as diagnosis, patient monitoring, and treatment recommendations, which might be seen as a challenge to the traditional roles of medical professionals.
This threat can affect the acceptance of AI, as healthcare professionals may feel that their expertise and human touch are undervalued in favor of automation. |
the acceptance of AI in healthcare, particularly studies that explore the psychosocial factors and perceived threats related to AI adoption by healthcare professionals. These types of studies often focus on how AI may be seen as a competitor or a tool that could alter the roles and job security of medical staff. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
According to the article, **designing human-centred AI systems** is essential for increasing AI acceptability among medical professionals. Human-centred design focuses on making AI systems intuitive, user-friendly, and tailored to meet the needs of healthcare providers. This approach helps to ensure that AI tools are integrated into clinical workflows effectively and that they enhance the decision-making process without overwhelming or replacing healthcare professionals. By designing systems that prioritize the user experience, healthcare workers are more likely to trust and adopt AI technologies. |
the concept of human-centered design for AI systems, particularly in healthcare, is a well-established approach in AI and HCI (Human-Computer Interaction) literature. It emphasizes creating technology that supports users (healthcare professionals, in this case) rather than replacing them, ensuring that AI solutions are designed to work effectively with humans in complex environments like medical settings. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
According to the article, the **'system usage'** category of AI acceptability factors includes **factors like value proposition and integration with workflows**. This category emphasizes how AI systems fit into the daily routines of healthcare professionals, including their perceived usefulness and how easily they integrate with existing workflows and systems. The **value proposition** refers to the benefits AI brings to medical professionals, such as improving diagnostic accuracy, efficiency, or patient care, while **integration with workflows** refers to how seamlessly AI systems can be adopted without disrupting the existing work processes in healthcare settings. |
Technology Acceptance Models (TAM): Such as the Unified Theory of Acceptance and Use of Technology (UTAUT), which highlight the importance of perceived usefulness (value proposition) and ease of use (integration with workflows) in technology adoption. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
Ethicality plays a significant role in AI acceptability among healthcare professionals because it influences how well AI systems align with medical ethics, patient rights, and healthcare values. If an AI system is perceived as incompatible with these values or raises concerns about fairness, transparency, or privacy, healthcare professionals may be less likely to trust and adopt it. Ethical considerations are central to ensuring that AI tools are used in ways that benefit patients while respecting their rights and dignity. |
The statement "Affects Views On AI Based On Compatibility With Professional Values" is derived from research that explores the ethical implications of AI adoption in healthcare settings. Ethical considerations are a significant factor in determining healthcare professionals' acceptance of AI technologies. AI systems that align with the core values of healthcare, such as patient confidentiality, fairness, and autonomy, are more likely to be embraced by medical professionals.
Such research typically highlights how AI systems must be designed and deployed in ways that respect ethical principles, including:
Patient privacy: Ensuring AI systems comply with regulations such as HIPAA or GDPR.
Transparency and fairness: Addressing biases in AI algorithms and ensuring that AI decisions can be explained and justified.
Equity in healthcare: Avoiding disparities in healthcare access or outcomes due to AI biases. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
According to the article, the methodological approach emphasized for future AI acceptability studies is **considering user experience and system integration deeply**. This approach highlights the importance of ensuring that AI technologies are not only effective but also intuitive, user-friendly, and easily integrated into existing healthcare workflows. By focusing on the experiences of healthcare professionals and the seamless incorporation of AI into their daily tasks, future research can better assess how AI tools are adopted and used in real-world healthcare settings.
This methodological approach helps ensure that AI solutions meet both the technical needs of healthcare professionals and their usability preferences, improving overall acceptance and effectiveness. |
"Designing Human-Centered AI Systems" (Shneiderman, B. et al., 2020): This study emphasizes the importance of integrating human-centered design principles into AI systems. It argues that AI tools in healthcare should be designed to support healthcare professionals, with an emphasis on their usability and smooth integration into clinical workflows. It also highlights the need to consider healthcare professionals' perspectives, needs, and concerns for AI systems to be accepted. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
The primary objective of using human embryonic stem cells in treating Parkinson’s disease is **to replace lost dopamine neurons**. Parkinson’s disease is characterized by the degeneration of dopamine-producing neurons in the brain, leading to motor control issues. Human embryonic stem cells have the potential to differentiate into dopamine-producing neurons, which could help restore normal brain function and alleviate symptoms of Parkinson's disease. This approach aims to replace the damaged or lost neurons and improve the patient's motor function and quality of life. |
The primary objective of using human embryonic stem cells in treating Parkinson's disease is to replace lost dopamine neurons. Parkinson’s disease results from the degeneration of dopamine-producing neurons in the brain, leading to motor control difficulties. Human embryonic stem cells (hESCs) have the potential to differentiate into dopamine-producing neurons, which can potentially restore dopamine levels and alleviate symptoms related to the disease.
Research has focused on transplanting these stem cells into patients to restore lost functions. One promising approach is to purify dopaminergic progenitor cells from stem cells and transplant them into the affected areas of the brain. This could lead to improved motor control and overall quality of life for patients, as shown in experimental models. Additionally, efforts are underway to eliminate the risk of tumor formation from pluripotent stem cells and enhance the efficacy of this treatment by refining differentiation protocols
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Rats |
|
The STEM-PD product, a stem cell-based treatment, was tested for safety and efficacy using **rats** in preclinical studies. These studies typically involve rodents like rats and mice, as they are commonly used in biomedical research due to their genetic similarities to humans and their well-understood biological systems. However, the specific details of testing can vary depending on the product's development and regulatory requirements. |
The information regarding the use of rats in testing the STEM-PD product is likely based on preclinical safety and efficacy studies conducted during its development, which would be published in scientific literature or regulatory documents. However, I couldn't find a specific reference to a particular study for the exact product you're asking about. If you are referring to a specific regulatory filing or scientific article, it would be helpful to look at the published preclinical research in peer-reviewed journals or consult the product's clinical trial documents for more specific details.
Stem cell-based products like STEM-PD are usually tested in animals like rats, mice, and sometimes pigs or rabbits in accordance with regulatory guidelines from organizations such as the FDA or EMA, to assess safety, potential toxicity, and effectiveness before human clinical trials. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
9 months |
|
Preclinical safety studies for stem cell-based treatments often last around 6 months to assess both short-term and medium-term effects. This duration allows researchers to gather enough data on the safety, efficacy, and potential side effects of the treatment. |
the STEM-PD product, a stem cell-based treatment for Parkinson's Disease, mentions that preclinical safety studies were conducted over a 39-week period in rats. This study followed Good Laboratory Practice (GLP) standards and assessed various safety measures, including toxicity, tumorigenicity, and biodistribution. This long duration was critical for ensuring the product's safety before it entered clinical trials
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
The clinical trial phase mentioned for **STEM-PD** is **Phase I/IIa**. This phase involves initial testing of the stem cell therapy in humans, focusing on safety, dose determination, and early efficacy. The trial aims to assess the product's feasibility in treating Parkinson's Disease using dopamine progenitor cells derived from human pluripotent stem cells. |
The Phase I/IIa clinical trial for STEM-PD is designed to test the safety, dosage, and initial efficacy of the stem cell therapy in human patients with Parkinson's Disease. This phase is crucial for assessing the feasibility of using dopamine progenitor cells derived from human pluripotent stem cells to treat the disease. The study involves transplanting these cells into patients' brains, with the goal of seeing if they can mature into functional dopamine-producing neurons. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
The STEM-PD product is manufactured under GMP-compliant conditions (Good Manufacturing Practice). This ensures that the production of the dopamine progenitor cells is done in a controlled, regulated environment that meets safety and quality standards required for clinical use. The manufacturing process involves using human pluripotent stem cells that are differentiated into dopamine progenitor cells with high efficiency, ensuring consistency and reliability for use in the clinical trials. |
The manufacturing process for STEM-PD involves producing dopamine progenitor cells derived from human pluripotent stem cells under GMP-compliant conditions (Good Manufacturing Practice). This ensures that the production adheres to strict quality control standards, ensuring the safety and consistency of the cells used in clinical trials. The cells are differentiated into dopamine progenitor cells with high efficiency to provide reliable and effective treatment for Parkinson's Disease |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
the safety of the STEM-PD product in rats was confirmed by the fact that there were no adverse effects or tumor formation. The study demonstrated that the transplanted dopamine progenitor cells survived long-term in the rats' brains, matured into dopamine-producing neurons, and did not exhibit signs of toxicity, tumor formation, or abnormal cell distribution outside the intended brain area
|
The safety of the **STEM-PD** product in rats was confirmed by the fact that there were no adverse effects or tumor formation. In preclinical studies, transplanted dopamine progenitor cells survived and matured into dopamine-producing neurons without showing any signs of toxicity, tumor growth, or abnormal cell migration outside the targeted brain area. This supports the safety profile of **STEM-PD** for its intended clinical applications.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
The key finding in the efficacy study of **STEM-PD** in rats was that **transplanted cells reversed motor deficits in rats**. The study demonstrated that the dopamine progenitor cells, when transplanted into the rats' brains, matured into functional dopamine-producing neurons, which effectively reversed motor deficits associated with Parkinson's Disease in the animal models. This positive outcome indicates the potential for **STEM-PD** to provide therapeutic benefits for Parkinson's patients. |
In the efficacy study of STEM-PD in rats, a key finding was that transplanted cells reversed motor deficits in animal models of Parkinson's Disease (PD). This was a significant result, as the dopamine progenitor cells were able to mature into dopamine-producing neurons and improve motor function in the rats, which are symptoms commonly seen in Parkinson's patients
THE STEM-PD CLINICAL TRIAL
THE STEM-PD CLINICAL TRIAL
. This result suggests that STEM-PD has the potential to help alleviate motor symptoms in humans as well, marking a promising step in the development of stem cell-based therapies for Parkinson's Disease |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
LMX1A and EN1 |
|
The purity of the **STEM-PD** batch was assessed using specific markers related to dopamine progenitors, including **LMX1A** and **EN1**. These markers are known to be expressed in midbrain dopaminergic (mDA) progenitor cells, helping to ensure the specificity and purity of the differentiated cells. In addition to these markers, **FOXA2** and **OTX2** were also noted in the characterization of midbrain dopaminergic progenitors, confirming the cell lineage relevant for Parkinson's Disease therapy |
the purity of STEM-PD used markers such as LMX1A and EN1 to confirm the identity of midbrain dopaminergic (mDA) progenitor cells. Additional markers like FOXA2 and OTX2 were also employed to verify the lineage and ensure the cells' suitability for Parkinson's Disease therapy. This study focused on ensuring high-purity and lineage specificity for cell-based treatments
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
FGF8b and SHH are crucial in directing the differentiation of stem cells into dopamine progenitor cells, specifically guiding their development into neural lineages appropriate for Parkinson's Disease treatment. These growth factors help pattern the cells for the desired neural fate |
The use of **FGF8b** and **SHH** to guide stem cell differentiation into dopamine progenitor cells is a well-documented strategy for directing cell patterning toward specific neural fates. These factors are crucial for ensuring that stem cells develop into the appropriate cell types for Parkinson's Disease treatment. For more details, you can explore the specific research on stem cell differentiation and the role of growth factors in **STEM-PD**. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
A key outcome measured in the preclinical trials for efficacy in rats was the **recovery of motor function**. The study demonstrated that dopamine progenitor cells, once transplanted, were able to reverse motor deficits associated with Parkinson’s Disease, showing the potential for improving motor abilities in animal models. |
In the preclinical trials for STEM-PD using rats, one of the key outcomes measured was the recovery of motor function. The studies demonstrated that transplanted dopamine progenitor cells were able to effectively reverse motor deficits associated with Parkinson's Disease in the animal models. This outcome suggests that the transplanted cells could restore motor abilities, making them a promising candidate for future therapies in human patients with Parkinson's Disease |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|